首页> 美国卫生研究院文献>Open Medicine >Resectable Single Hepatic Epithelioid Hemangioendothelioma in the Left Lobe of the Liver: A Case Report
【2h】

Resectable Single Hepatic Epithelioid Hemangioendothelioma in the Left Lobe of the Liver: A Case Report

机译:肝左叶可切除的单肝上皮样血管内皮瘤:一例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hepatic epithelioid hemangioendothelioma (HEHE) is an extremely rare malignancy of vascular origin. When most patients with HEHE are diagnosed, they have a diffuse nodular phenotype, which is usually unresectable. A single nodular phenotype is found in only a small proportion (13%) of patients, and most are reported to be located in the right lobe of the liver. Although the prognosis of HEHE is considered more favorable than that of other hepatic malignant tumors, the 5-year survival rate is reported to be 64% after treatment. Herein, we present an unusual case of resectable HEHE of a single nodular type in the left lobe of the liver. The patient survived 15 years without recurrence after the multimodal treatment of radical resection and postoperative chemotherapy with thalidomide. The aim of the present study is to emphasize that multimodal treatment of radical resection followed by chemotherapy with thalidomide may achieve a relatively good survival outcome in patients with resectable HEHE of a single nodular type.
机译:肝上皮样血管内皮瘤(HEHE)是一种极为罕见的血管源性恶性肿瘤。当诊断出大多数HEHE患者时,他们具有弥散性结节表型,通常无法切除。仅一小部分(13%)患者发现了单个结节表型,据报道大多数位于肝脏的右叶。尽管HEHE的预后被认为比其他肝恶性肿瘤的预后更好,但据报道治疗后的5年生存率为64%。在本文中,我们介绍了肝左叶单结节型可切除HEHE的罕见病例。根治性切除的多模式治疗和沙利度胺的术后化疗后,患者存活了15年,没有复发。本研究的目的是强调,对于单一结节型可切除HEHE患者,多模式治疗根治性切除术后联合沙利度胺化疗可能会获得相对较好的生存结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号